Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
Registry Multicenter, prospective observational study Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
- Trial name
- NCT03286738
- Testing
- FOLFIRI, target agent
- Where
- South Korea
- Volunteers
- 1,800 people
- Sponsor
- Joong Bae Ahn
Colorectal Cancer Metastatic
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
This study aims to determine the efficacy, safety, and tolerability of the sequential addition of immune-modulating therapy to standard-of-care therapy of microsatellite-stable (MSS)/mismatch repair-proficient (pMMR) metastatic…
- Trial name
- METIMMOX (NCT03388190)
- Testing
- Nivolumab, FLOX
- Where
- 5 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006115
- Testing
- FOLFIRI regimen, FOLFOX regimen, fluorouracil
- Where
- 16 sites in France
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have recurrent or persistent metastatic colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00023933
- Testing
- iodine I 131 monoclonal antibody CC49-deltaCH2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the…
- Trial name
- NCT01075048
- Testing
- Tivantinib, Cetuximab, Irinotecan
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 131 people
- Sponsor
- Daiichi Sankyo
Liver Cancer, Colorectal Cancer
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
Patients with resectable liver metastases of colorectal origin will be assigned to laparoscopic liver resection or conventional open liver surgery. Blood samples will be drawn preoperatively and 24 hours after resection.
- Conditions
- Liver Cancer, Colorectal Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT03131778
- Testing
- Liver resection
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Colorectal Cancer
Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI
Colon cancer with metastase in the diagnose time account for one significant rate and has a increasing trend. The treatment result of this patient group rests modest.
- Trial name
- NCT03504618
- Testing
- FOLFOXIRI
- Where
- Vietnam
- Volunteers
- 39 people
- Sponsor
- Hanoi Medical University
Metastasis Colorectal Cancer
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
- Trial name
- NCT04179084
- Testing
- fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Cancer
Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with metastatic…
- Trial name
- NCT00003220
- Testing
- bryostatin 1
- Where
- 2 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Colorectal Cancer
Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Molecular subtypes make difference on clinicopathologic features and response to chemotherapy and targeted agents as well as prognosis.
- Trial name
- NCT05522738
- Testing
- Combination: Fruquintinib + FOLFIRI
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Chinese PLA General Hospital
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer
Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.
3rd line standard treatment of patients with metastatic colorectal cancer (CRC) harboring K-ras wild type consists of anti-EGFR treatment with either cetuximab or panitumumab.
- Trial name
- NCT01691391
- Testing
- (Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
This phase I/II trial tests the safety, side effects, best dose, and efficacy of FOLFOX and bevacizumab in combination with botensilimab and balstilimab (3B-FOLFOX) in treating patients with microsatellite stable (MSS) colorectal…
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT05627635
- Testing
- Balstilimab, Bevacizumab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Metastatic Colorectal Cancer
A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab
The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving…
- Trial name
- NCT02673710
- Testing
- No intervention
- Where
- 23 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Metastatic Colorectal Cancer
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
FC-8 is a Phase II, multi-center randomized study of a continuation regimen of 5-FU/LV with ziv-aflibercept or 5-FU/LV alone (control arm) following the induction regimen of mFOLFOX6 and ziv-aflibercept as first-line therapy for…
- Trial name
- NCT01889680
- Testing
- 5-FU, LV, ziv-aflibercept
- Sponsor
- NSABP Foundation Inc
Recurrent Colon Cancer, Recurrent Rectal Cancer
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
This randomized phase III trial is studying giving irinotecan and cetuximab together with bevacizumab to see how well it works compared with giving irinotecan and cetuximab alone in treating patients with metastatic colorectal…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT00499369
- Testing
- irinotecan hydrochloride, leucovorin calcium, fluorouracil
- Where
- 382 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Adenocarcinoma, Colon Cancer
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Data from a prior phase II study of single agent cabozantinib in metastatic, refractory colorectal cancer (NCT03542877) combined with the compelling preclinical data in colorectal mouse models utilizing cabozantinib combined with…
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer
- Trial name
- NCT04963283
- Testing
- Cabozantinib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Colorado, Denver
Metastatic Colorectal Cancer
Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer
This study will evaluate the efficacy of FOLOFOXIRI plus Cetuximab combination in young patients with good performance status with unresectable metastatic colorectal cancer.
- Trial name
- NCT00689624
- Testing
- Irinotecan, Leukovorin, Oxaliplatin
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- University Hospital of Crete
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.